Skip to content
Open access · CC-BY via OpenAlex

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y. Spiegel, Shabnum Patel, Lori S. Muffly, Nasheed Mohammad Hossain, Jean S. Oak, John H. Baird, Matthew Joshua Frank, Parveen Shiraz, Bita Sahaf, Juliana K. Craig, María Esther Iglesias, Sheren F Younes, Yasodha Natkunam, Michael G. Ozawa, Eric Yang

Nature Medicine · 2021 · ▲ 613 citations

Abstract

Abstract Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19 − or CD19 lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial ( NCT03233854 ) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL ( n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL ( n = 21), 62% of patients responded with 29% CR. Relapses were CD19 −/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22 −/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1038/s41591-021-01436-0
Canonical
link ↗
Fetched
2026-10-01 MST

Cite this

APA
Spiegel, J.Y., Patel, S., Muffly, L.S., Hossain, N.M., Oak, J.S., Baird, J.H., Frank, M.J., Shiraz, P., Sahaf, B., Craig, J.K., Iglesias, M.E., Younes, S.F., Natkunam, Y., Ozawa, M.G., Yang, E., Tamaresis, J.S., Chinnasamy, H., Ehlinger, Z.J., Reynolds, W.D., &amp; Lynn, R.C. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <em>Nature Medicine</em>. https://doi.org/10.1038/s41591-021-01436-0
Vancouver
Spiegel JY, Patel S, Muffly LS, Hossain NM, Oak JS, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. 2021. doi:10.1038/s41591-021-01436-0.
BibTeX
@article{jay2021CARTce, title = {CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial}, author = {Jay Y. Spiegel and Shabnum Patel and Lori S. Muffly and Nasheed Mohammad Hossain and Jean S. Oak and John H. Baird and Matthew Joshua Frank and Parveen Shiraz and Bita Sahaf and Juliana K. Craig and María Esther Iglesias and Sheren F Younes and Yasodha Natkunam and Michael G. Ozawa and Eric Yang and John S. Tamaresis and Harshini Chinnasamy and Zachary J. Ehlinger and Warren D. Reynolds and Rachel C. Lynn and Maria Caterina Rotiroti and Nikolaos Gkitsas-Long and Sally Arai and Laura Johnston and Robert Lowsky}, journal = {Nature Medicine}, year = {2021}, doi = {10.1038/s41591-021-01436-0}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings